Effect of Xiaoliu Forluma on tumor microenvironment and miR⁃532⁃3p expression in diffuse large B⁃cell lymphoma

Yan LIU; Changui LI; Xiaolin MA; Jiekai LI; Yacong SHAO; Hao LU; Yongming ZHOU

doi:10.16306/j.1008-861x.2022.03.003

您当前的位置：

首页 >

文章列表页 >

Effect of Xiaoliu Forluma on tumor microenvironment and miR⁃532⁃3p expression in diffuse large B⁃cell lymphoma

Clinical Research | 更新时间：2022-08-29

- Effect of Xiaoliu Forluma on tumor microenvironment and miR⁃532⁃3p expression in diffuse large B⁃cell lymphoma
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 36, Issue 3, Pages: 13-19(2022)
- 作者机构：
  
  1.上海中医药大学附属普陀医院（上海　200062）
  2.上海中医药大学附属岳阳中西医结合医院（上海　200437）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2022.03.003
  CLC：
扫描看全文
刘艳,李昌桂,马小淋等.消瘤方对弥漫大B细胞淋巴瘤肿瘤微环境及miR⁃532⁃3p表达的影响[J].上海中医药大学学报,2022,36(03):13-19.

LIU Yan,LI Changui,MA Xiaolin,et al.Effect of Xiaoliu Forluma on tumor microenvironment and miR⁃532⁃3p expression in diffuse large B⁃cell lymphoma[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(03):13-19.
刘艳,李昌桂,马小淋等.消瘤方对弥漫大B细胞淋巴瘤肿瘤微环境及miR⁃532⁃3p表达的影响[J].上海中医药大学学报,2022,36(03):13-19. DOI： 10.16306/j.1008-861x.2022.03.003.

LIU Yan,LI Changui,MA Xiaolin,et al.Effect of Xiaoliu Forluma on tumor microenvironment and miR⁃532⁃3p expression in diffuse large B⁃cell lymphoma[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(03):13-19. DOI： 10.16306/j.1008-861x.2022.03.003.

摘要

目的,2,观察消瘤方治疗弥漫大B细胞淋巴瘤（DLBCL）的临床疗效及对细胞因子、,miR,-,532,-,3p,、β-连环蛋白mRNA（,β,-,catenin ,mRNA）表达的影响。,方法,2,纳入DLBCL患者60例，随机分为对照组和治疗组，每组各30例；同时，纳入15例健康志愿者作为正常组。对照组患者给予常规的R-CHOP化疗方案治疗，治疗组患者在对照组治疗基础上联合消瘤方加减口服，两组疗程均为4个化疗周期。评价两组患者的临床疗效、中医证候疗效，检测所有纳入受试者的血清白介素（IL）-2、IL-4、IL-6、IL-10及外周血淋巴细胞,miR,-,532,-,3p,、,β,-,catenin, mRNA的表达水平。,结果,2,①治疗后，治疗组的临床总有效率为93.3%，对照组为80.0%，治疗组的疗效优于对照组（,P,<,0.05）。②治疗后，治疗组的中医证候疗效总有效率为96.7%，对照组为83.3%，治疗组的中医证候疗效优于对照组（,P,<,0.01）。③与正常组比较，两组患者治疗前的,miR,-,532,-,3p,表达水平均显著降低（,P,<,0.01）、,β,-,catenin, mRNA表达水平均显著升高（,P,<,0.01）；治疗后，两组患者的,miR,-,532,-,3p,表达水平均升高（,P,<,0.01）、,β,-,catenin, mRNA表达水平均降低（,P,<,0.01），且治疗组患者的,miR,-,532,-,3p,表达水平高于对照组（,P,<,0.01）、,β,-,catenin, mRNA表达水平低于对照组（,P,<,0.01）。④与正常组比较，两组患者治疗前的IL-4、IL-6、IL-10水平均显著升高（,P,<,0.01），IL-2水平均显著降低（,P,<,0.01）；治疗后，两组患者的IL-4、IL-6、IL-10水平均明显降低（,P,<,0.01），IL-2水平均明显升高（,P,<,0.01），且治疗组患者的IL-4、IL-6、IL-10水平低于对照组（,P,<,0.05），IL-2水平高于对照组（,P,<,0.05）。,结论,2,消瘤方联合化疗治疗DLBCL，能有效抑制肿瘤，改善临床症状和肿瘤微环境，其作用机制可能与调节,miR,-,532,-,3p,、,β,-,catenin ,mRNA的表达有关。

Abstract

Objective： To observe the clinical efficacy of Xiaoliu Forluma in the treatment of diffuse large B-cell lymphoma （DLBCL） and its influence on the expressions of cytokines， ,miR,-,532,-,3p, and ,β,-,catenin, mRNA.,Methods,2,Sixty patients of DLBCL were included and randomly divided into the control group and treatment group， 30 cases in each group. Meanwhile， 15 healthy volunteers were included as the normal group. The patients in the control group were treated with routine R-CHOP chemotherapy， and the patients in the treatment group were treated with modified Xiaoliu Forluma orally based on the treatment of the control group. The treatment course of both groups was 4 chemotherapy cycles. The clinical efficacy and the efficacy of traditional Chinese medicine syndrome in both groups were evaluated. The levels of serum interleukin （IL）-2， IL-4， IL-6 and IL-10 and the expression levels of ,miR,-,532,-,3p, and ,β,-,catenin ,mRNA in peripheral blood lymphocyte of all the subjects were detected.,Results,2,①After treatment， the total clinical effective rate was 93.3% in the treatment group and 80.0% in the control group， and the effect of the treatment group was superior to that in the control group （,P,<,0.05）. ②After treatment， the total effective rate on traditional Chinese medicine syndrome was 96.7% in the treatment group and 83.3% in the control group， and the traditional Chinese medicine syndrome effect of the treatment group was superior to those in the control group （,P,<,0.01）. ③Compared with the normal group， the expression level of ,miR,-,532,-,3p, in the two groups before treatment was significantly decreased （,P,<,0.01）， and the expression level of ,β,-,catenin, mRNA was significantly increased （,P,<,0.01）. After treatment， the expression level of ,miR,-,532,-,3p, in the two groups was increased （,P,<,0.01）， the expression level of ,β,-,catenin, mRNA was decreased （,P,<,0.01）， and the expression level of ,miR,-,532,-,3p, in the treatment group was higher than that in the control group （,P,<,0.01）， the expression level of ,β,-,catenin, mRNA was lower than that in the control group （,P,<,0.01）. ④Compared with the normal group， the levels of IL-4， IL-6 and IL-10 in the two groups before treatment were significantly increased （,P,<,0.01）， and the level of IL-2 was significantly decreased （,P,<,0.01）. After treatment， the levels of IL-4， IL-6 and IL-10 in the two groups were significantly decreased （,P,<,0.01）， the level of IL-2 was significantly increased （,P,<,0.01）， and the levels of IL-4， IL-6 and IL-10 in the treatment group were lower than those in the control group （,P,<,0.05）， the level of IL-2 was higher than that in the control group （,P,<,0.05）.,Conclusion,2,Xiaoliu Formula combined with chemotherapy can effectively inhibit the tumor and improve the clinical symptoms and the tumor microenvironment， and its mechanisms may be related to regulating the expression of ,miR,-,532,-,3p, and ,β,-,catenin ,mRNA.

关键词

弥漫大B细胞淋巴瘤消瘤方肿瘤微环境miR-532-3pβ-catenin mRNA

Keywords

diffuse large B-cell lymphomaXiaoliu Formulatumor microenvironmentmiR-532-3pβ-catenin mRNA

references

GHIELMINI M， VITOLO U， KIMBY E， et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1： diffuse large B-cell lymphoma （DLBCL）， follicular lymphoma （FL） and chronic lymphocytic leukemia （CLL）［J］. Ann Oncol， 2013， 24（3）： 561-576.

MIRANDA-FILHO A， PIÑEROS M， ZNAOR A， et al. Global patterns and trends in the incidence of non-Hodgkin lymphoma［J］. Cancer Causes Control， 2019， 30（5）：489-499.

KUBUSCHOK B， HELD G， PFREUNDSCHUH M. Management of diffuse large B-cell lymphoma （DLBCL）［J］. Cancer Treat Res， 2015， 165： 271-288.

RAUT L S， CHAKRABRTI P P. Management of relapsed-refractory diffuse large B cell lymphoma［J］. South Asian J Cancer， 2014， 3（1）： 66-70.

RAMESH P， SHIVDE R， JAISHANKAR D， et al. A Palette of Cytokines to Measure Anti-Tumor Efficacy of T Cell-Based Therapeutics［J］. Cancers （Basel）， 2021， 13（4）： 821.

EDLEFSEN K L， MARTÍNEZ-MAZA O， MADELEINE M M， et al. Cytokines in serum in relation to future non-Hodgkin lymphoma risk： evidence for associations by histologic subtype［J］. Int J Cancer， 2014， 135（4）： 913-922.

ATTIA F M， HASSAN A M， EL-MARAGHY N N， et al. Clinical significance of suppressor of cytokines signalling-3 mRNA expression from patients with non-Hodgkin lymphoma under chemotherapy［J］. Cancer Biomark， 2011-2012， 11（1）： 41-47.

赖芸，陈子珺. 中药复方对肿瘤微环境影响的研究进展［C］//中华中医药学会. 中华中医药学会第十四次中医方剂学学术年会论文集. 哈尔滨：中华中医药学会第十四次中医方剂学学术年会， 2014.

李捷凯，鲍计章，朱文伟，等. 消瘤方加减治疗化疗后正虚痰凝型弥漫大B细胞淋巴瘤60例临床观察［J］.中医杂志， 2022， 63（4）： 349-355.

孙瑞芳， STEIN H，王晋芬. 2016年版WHO淋巴瘤分类新进展及其应用［J］. 白血病·淋巴瘤， 2016， 25 （6）： 321-321.

张素平. 昆藻逆瘤汤加味治疗初治弥漫大B细胞淋巴瘤（气郁痰凝型）的临床疗效观察［D］. 郑州：河南中医药大学， 2018.

连粉红. 抑瘤消核方联合R-CHOP方案治疗弥漫大B细胞淋巴瘤的临床研究［D］. 兰州：甘肃中医药大学， 2019.

中华医学会血液学分会，中国抗癌协会淋巴瘤专业委员会. 中国弥漫大B细胞淋巴瘤诊断与治疗指南（2013年版）［J］. 中华血液学杂志， 2013， 34（9）： 816-819.

郑筱萸. 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002.

LIU Y， LI Q Y， DAI Y Z， et al. miR-532-3p Inhibits Proliferation and Promotes Apoptosis of Lymphoma Cells by Targeting β-catenin［J］. J Cancer， 2020， 11（16）：4762-4770.

PRENDERGAST G C， JAFFEE E M. Cancer immunologists and cancer biologists： why we didn’t talk then but need to now［J］. Cancer Res， 2007， 67（8）： 3500-3504.

BERRAONDO P， SANMAMED M F， OCHOA M C， et al. Cytokines in clinical cancer immunotherapy［J］. Br J Cancer， 2019， 120（1）： 6-15.

ZHONG H J， CHEN J， CHENG S， et al. Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin’s lymphoma［J］. EBioMedicine， 2019， 41： 167-174.

VENDRAME E， Hussain S K， Breen E C， et al. Serum levels of cytokines and biomarkers for inflammation and immune activation， and HIV-associated non-Hodgkin B-cell lymphoma risk［J］. Cancer Epidemiol Biomarkers Prev， 2014， 23（2）： 343-349.

PAN T， ZHANG F， LI F， et al. Shikonin blocks human lung adenocarcinoma cell migration and invasion in the inflammatory microenvironment via the IL-6/STAT3 signaling pathway［J］. Oncol Rep， 2020， 44（3）： 1049-1063.

徐伟，方思佳，关然，等. 白术多糖对小鼠淋巴细胞的免疫调节作用［J］. 中国免疫学杂志， 2020， 36（13）： 1573-1577.

NUSSE R， CLEVERS H. Wnt/β-Catenin Signaling， Disease， and Emerging Therapeutic Modalities［J］. Cell， 2017， 169（6）： 985-999.

BOGNAR M K， VINCENDEAU M， ERDMANN T， et al. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas［J］. Oncogene， 2016， 35（32）：4269-4281.

Views

188

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction methods of 3D multicellular co⁃culture model based on tumor microenvironment

Study on effect of exosomes from different cell sources in tumor microenvironment on tumor drug resistance and intervention of traditional Chinese medicine

Co-culture system of C26 colon cancer cells and RAW264.7 macrophages induces myotube atrophy in C2C12 cells and protective effect of glycyrrhiza polysaccharides

Mechanism and advantages of traditional Chinese medicine in remodeling tumor microenvironment

Related Author

No data

Related Institution

Institute of Interdiscplinary Integrative Medicine Research， Shanghai University of Traditional Chinese Medicine

School of Life Science， Huaibei Normal University

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

⁰